Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
Targeted delivery and controlled release of inactive platinum (Pt) prodrugs may offer a new approach to improve the efficacy and tolerability of the Pt family of drugs, which are used to treat 50% of all cancers today. Using prostate cancer (PCa) as a model disease, we previously described the engin...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2011
|
| Online Access: | http://hdl.handle.net/1721.1/65115 https://orcid.org/0000-0002-2693-4982 https://orcid.org/0000-0002-2640-3006 |